Over the past week, the U.S. House of Representatives supported three bills concerning cryptocurrency that investors find optimistic for the industry as a whole. Two of these bills aim to establish guidelines for stablecoins and digital assets. Notably, President Donald Trump has already signed into law one of these bills, known as the Genius Act, which pertains to stablecoins, following its approval by both the House and Senate.
In my observation, Buffett invests in equities that offer exceptional value compared to their underlying businesses. If the market is willing to overpay for a particular stock, he’s content to part ways with it. This strategy keeps him largely out of the fray when stocks become excessively priced.
On Friday evening, President Donald Trump gave his approval to the Cryptocurrency Act (Genius Act) as law. This act was one of several pieces of legislation approved by the U.S. House of Representatives during “Crypto Week,” and aims to establish a structure for stablecoins – digital currencies tied to commodities or fiat money. Many investors anticipate that these passed bills could foster a more favorable regulatory landscape for cryptocurrency in the future.
In many instances within the biotechnology sector, Summit Therapeutics’ impressive growth can be attributed to advancements in clinical trials with its foremost drug candidate. Despite the substantial progress it has made recently, there may still be a good opportunity for investors to jump aboard given the early stages of its success.
These five ETFs could be excellent choices for long-term investors. You don’t have to buy all of them, but if you have $1,000 available for investment, any one of these would make a wise initial step. Keep in mind that $1,000 is just a starting point; it’s beneficial to regularly invest in ETFs every month over the long term.
As an ardent follower of the market, I was intrigued when I noticed Navitas’ stock surge following their announcement about reporting earnings on August 4th. It wasn’t so much about what they would report as it was the simple fact that they were reporting at all. Surprisingly, investors are snapping up shares left and right, not knowing whether the upcoming earnings news will bring good or bad tidings. This unexpected enthusiasm is a fascinating study in market dynamics!
The surge in Plug Power’s stock price can be easily explained: This morning, Biju Perincheril from Susquehanna upped his price target for Plug stock by a significant 80%, raising it from $1 per share to $1.80. However, the real question is whether this single analyst’s opinion justifies a 8.1% increase in Plug Power’s stock price.
During the second quarter of 2025, Redhawk Wealth Advisors boosted its ownership in Invesco QQQ Trust Series 1 (QQQ) by purchasing an additional 7,181 shares, as reported in a filing made to the Securities and Exchange Commission on July 10, 2025. The deal was worth approximately $3.57 million, resulting in the fund owning a total of 18,597 QQQ shares by June 30, 2025. By July 21, 2025, this holding had increased to a value of around $10.44 million.
The company that thrived during the real estate boom caused by the pandemic has now failed, due to rising interest rates and a struggling housing market. Many homeowners who took advantage of low mortgage rates during the pandemic are hesitant to sell their properties, leading to a decline in the business. This stock has plummeted, with its value dropping 96% from its highest point in 2021.
In my observation, we’ve arrived at Rhythm Pharmaceuticals (RYTM), a mid-sized biotech company, causing quite a stir in the broader weight loss market. Specifically, it’s making waves within a particular subsector. Notably, this company just announced promising outcomes that significantly boosted its stock value. So, is this an enticing investment opportunity given these recent advancements? Let’s delve deeper to find out.